Skip to main content

Table 1 Patients’ characteristics at baseline

From: The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study

Characteristics n (%)
  (n = 13,559)
Age, in years, median (IQR) 34.6 (28.4–41.8)
Male 9937 (73.3)
Immigrant 1667 (12.3)
Intravenous drug use 4799 (35.4)
HBV/HCV co-infection 5890 (43.4)
HIV-RNA viral load undetectable 3082 (25.8)
ART 4532 (33.4)
CD4 cell count, median (IQR) 378 (214–571)
 0–49 611 (5.1)
 50–99 633 (5.3)
 100–199 1507 (12.56)
 200–349 2747 (22.9)
 350–499 2577 (21.5)
 ≥500 3932 (32.8)
CD4/CD8, median (IQR) 0.37 (0.20–0.61)
 <0.3 2215 (39.7)
 0.3–0.45 1119 (20.1)
 ≥0.45 2244 (40.2)
Lymphocytes, median (IQR) 1856 (1361–2390)
Neutrophils, median (IQR) 2694 (2000–3619)
Platelets, median (IQR) 210,999 (166,000–260,000)
NLR, median (IQR) 1.47 (1.03–2.17)
PLR, median (IQR) 109.9 (79.6–155.3)
  1. Missing values: Immigrant 81 (0.6 %); HIV-RNA viral load undetectable 1609 (11.9 %), CD4 cell count 1552 (11.5 %), CD4/CD8 7981 (58.9 %), Lymphocytes 2607 (19.2 %); Neutrophils 4023 (29.7 %); Platelets 2553 (18.8 %); NLR 4978 (36.7 %); PLR 3107 (22.9 %)
  2. IQR interquartile range, HBV hepatitis B virus, HCV hepatitis C virus, ART antiretroviral therapy, NLR neutrophil to lymphocytes ratio, PLR platelets to lymphocytes ratio